Managing complications following lung transplantation

References

• Christie JD, Edwards LB, Aurora P et al. Registry of the International Society for Heart and Lung Transplantation: twenty-fifth official adult lung and heart/lung transplantation report – 2008. J. Heart Lung Transplant.27, 957–969 (2008).
   PubMed Web of Science ®Google Scholar
• de Perrot M, Liu M, Waddell TK, Keshavjee S. Ischemia–reperfusion-induced lung injury. Am. J. Respir. Crit. Care Med.167, 490–511 (2003).
   PubMed Web of Science ®Google Scholar
• Christie JD, Carby M, Bag R, Corris P, Hertz M, Weill D. Report of the ISHLT working group on primary lung graft dysfunction: part II. Definition. J. Heart Lung Transplant.24, 1454–1459 (2005).
   PubMed Web of Science ®Google Scholar
• Christie JD, Kotloff RM, Ahya VN et al. The effect of primary graft dysfunction on survival after lung transplantation. Am. J. Respir. Crit. Care Med.171, 1312–1316 (2005).
   PubMedGoogle Scholar
• Daud SA, Yusen RD, Meyers BF et al. Impact of immediate primary lung allograft dysfunction on bronchiolitis obliterans syndrome. Am. J. Respir. Crit. Care Med.175, 507–513 (2007).
   PubMed Web of Science ®Google Scholar
• Kermeen FD, McNeil KD, Fraser JF et al. Resolution of severe ischemia–reperfusion injury post-lung transplantation after administration of endobronchial surfactant. J. Heart Lung Transplant.26, 850–856 (2007).
   PubMed Web of Science ®Google Scholar
• Zamora MR, Davis RD, Keshavjee SH et al. Complement inhibition attenuates human lung transplant reperfusion injury: a multicenter trial. Chest116, 46S (1999).
   Google Scholar
• Wittwer T, Grote M, Oppelt P, Franke U, Schaefers HJ, Wahlers T. Impact of PAF antagonist BN 52021 (ginkolide β) on post-ischemic graft function in clinical lung transplantation. J. Heart Lung Transplant.20, 358–363 (2001).
   PubMed Web of Science ®Google Scholar
• Shargall Y, Guenther G, Ahya VN, Ardehali A, Singhal A, Keshavjee S. Report of the ISHLT Working Group on primary lung graft dysfunction: part VI. Treatment. J. Heart Lung Transplant.24, 1489–1500 (2005).
   PubMed Web of Science ®Google Scholar
• Schmid RA, Boehler A, Speich R, Frey HR, Russi EW, Weder W. Bronchial anastomotic complications following lung transplantation: still a major cause of morbidity? Eur. Respir. J.10, 2872–2875 (1997).
   PubMedGoogle Scholar
• Murthy SC, Blackstone EH, Gildea TR et al.; Members of Cleveland clinic’s pulmonary transplant team. Impact of anastomotic airway complications after lung transplantation. Ann. Thorac. Surg.84, 401–409 (2007).
   PubMedGoogle Scholar
• McAnally KJ, Valentine VG, LaPlace SG, McFadden PM, Seoane L, Taylor DE. Effect of pre-transplantation prednisone on survival after lung transplantation. J. Heart Lung Transplant.25, 67–74 (2006).
   PubMed Web of Science ®Google Scholar
• Groetzner J, Kur F, Spelsberg F et al.; Munich Lung Transplant Group. Airway anastomosis complications in de novo lung transplantation with sirolimus-based immunosuppression. J. Heart Lung Transplant.23, 632–638 (2004).
   PubMed Web of Science ®Google Scholar
• Thistlewaite PA, Yung G, Kemp A et al. Airway stenoses after lung transplantation: incidence, management, and outcome. J. Thorac. Cardiovasc. Surg.136, 1569–1575 (2008).
   PubMedGoogle Scholar
• Mughal MM, Gildea TR, Murthy S, Pettersson G, DeCamp M, Mehta AC. Short-term deployment of self-expanding metallic stents facilitates healing of bronchial dehiscence. Am. J. Respir. Crit. Care Med.172, 768–771 (2005).
   PubMedGoogle Scholar
• Madden BP, Loke TK, Sheth AC. Do expandable metallic airway stents have a role in the management of patients with benign tracheobronchial disease? Ann. Thorac. Surg.82, 274–278 (2006).
   PubMed Web of Science ®Google Scholar
• Ferrer J, Roldan J, Roman A et al. Acute and chronic pleural complications in lung transplantation. J. Heart Lung Transplant.22, 1217–1225 (2003).
   PubMedGoogle Scholar
• Wahidi MM, Willner DA, Snyder LD, Hardison JL, Chia JY, Palmer SM. Diagnosis and outcome of early pleural space infection following lung transplantation. Chest135, 484–491 (2009).
   PubMed Web of Science ®Google Scholar
• Shitrit D, Izbicki G, Fink G et al. Late postoperative pleural effusion following lung transplantation: characteristics and clinical implications. Eur. J. Cardiovasc. Surg.23, 494–496 (2003).
   Google Scholar
• Sharples LD, McNeil K, Stewart S, Wallwork J. Risk factors for bronchiolitis obliterans: a systematic review of recent publications. J. Heart Lung Transplant.21, 271–281 (2002).
   PubMed Web of Science ®Google Scholar
• Cooper JD, Billingham M, Egan T et al. A working formulation for the standardization of nomenclature and for clinical staging of chronic dysfunction in lung allografts. J. Heart Lung Transplant.12, 713–716 (1993).
   PubMed Web of Science ®Google Scholar
• Hopkins PM, McNeil K. Evidence for immunosuppression in lung transplantation. Curr. Opin. Organ Transplant.13, 477–483 (2008).
   PubMedGoogle Scholar
• Hachem J, Yusen RD, Chakinala MM et al. A randomized controlled trial of tacrolimus versus cyclosporine after lung transplantation. J. Heart Lung Transplant.26, 1012–1018 (2007).
   PubMed Web of Science ®Google Scholar
• Estenne M, Hertz MI. Bronchiolitis obliterans after human lung transplantation. Am. J. Respir. Crit. Care Med.166, 440–444 (2002).
   PubMed Web of Science ®Google Scholar
• Stewart S, Fishbein MC, Snell GI et al. Revision of the 1996 working formulation for the standardization of nomenclature in the diagnosis of lung rejection. J. Heart Lung Transplant.26, 1229–1242 (2007).
   PubMed Web of Science ®Google Scholar
• Reams BD, Musselwhite LW, Zaas DW et al. Alemtuzumab in the treatment of refractory acute rejection and bronchiolitis obliterans syndrome after human lung transplantation. Am. J. Transplant.7, 2802–2808 (2007).
   PubMed Web of Science ®Google Scholar
• Magliocca JF, Knechtle SJ. The evolving role of alemtuzumab (campath 1H) for immunosuppressive therapy in organ transplantation. Transpl. Int.19(9), 705–714 (2006).
   PubMed Web of Science ®Google Scholar
• Lama VN, Murray S, Mumford JA et al. Prognostic value of bronchiolitis obliterans syndrome stage 0-p in single lung transplant recipients. Am. J. Respir. Crit. Care Med.172(3), 379–383 (2005).
   PubMedGoogle Scholar
• Hachem RR, Chakinala MM, Yusen RD et al. The predictive value of bronchiolitis obliterans syndrome stage 0-p. Am. J. Respir. Crit. Care Med.169, 468–472 (2004).
   PubMedGoogle Scholar
• Hachem RR, Khalifah AP, Chakinala MM et al. The significance of a single episode of minimal acute rejection after lung transplantation. Transplantation80, 1406–1413 (2005).
   PubMed Web of Science ®Google Scholar
• Bowdish ME, Arcasoy SM, Wilt JS et al. Surrogate markers and risk factors for chronic lung allograft dysfunction. Am. J. Transplant.4, 1171–1178 (2004).
   PubMed Web of Science ®Google Scholar
• Chalermskulrat W, Neuringer IP, Schmitz JL et al. Human leukocyte antigen mismatches predispose to the severity of bronchiolitis obliterans syndrome after lung transplantation. Chest123, 1825–1831 (2003).
   PubMedGoogle Scholar
• Snell GI, Valentine VG, Vitulo P et al.; RAD B159 Study Group. Everolimus versus azathioprine in maintenance lung transplant recipients: an international, randomized, double-blind clinical trial. Am. J. Transplant.6, 169–177 (2006).
   PubMed Web of Science ®Google Scholar
• Iacono AT, Johnson BA, Grgurich WF et al. A randomized trial of inhaled cyclosporine in lung-transplant recipients. N. Engl. J. Med.354, 141–150 (2006).
   PubMed Web of Science ®Google Scholar
• Behr J, Zimmermann G, Baumgartner R et al.; The Munich Lung Transplant Group. Lung deposition of a liposomal cyclosporine A inhalation solution in patients after lung transplantation. Curr. Opin. Organ Transplant.13, 477–483 (2008).
   PubMedGoogle Scholar
• Lopez-Boado YS, Rubin BK. Macrolides as immunomodulatory medications for the therapy of chronic lung diseases. Curr. Opin. Pharmacol.8, 286–291 (2008).
   PubMed Web of Science ®Google Scholar
• Crowley S, Egan JJ. Macrolide antibiotics and bronchiolitis obliterans following lung transplantation. Expert Rev. Anti Infect. Ther.3(6), 923–930 (2005).
   PubMedGoogle Scholar
• Gerhardt SG, McDyer JF, Girgis RE, Conte JV, Yang SC, Orens JB. Maintenance azithromycin therapy for brocnhiolitis obliterans: results of a pilot study. Am. J. Respir. Crit. Care Med.168, 121–125 (2003).
   PubMed Web of Science ®Google Scholar
• Verleden GM, Dupont LJ. Azithromycin therapy for patients with bronchiolitis obliterans syndrome after lung transplantation. Transplantation77, 1465–1467 (2004).
   PubMed Web of Science ®Google Scholar
• Yates B, Murphy DM, Forrest IA et al. Azithromycin reverses airflow obstruction in established bronchiolitis obliterans syndrome. Am. J. Respir. Crit. Care Med.172, 772–775 (2005).
   PubMed Web of Science ®Google Scholar
• Shitrit D, Bendayan D, Gidon S, Saute M, Bakal I, Kramer MR. Long-term azithromycin use for treatment of bronchiolitis obliterans syndrome in lung transplant recipients. J. Heart Lung Transplant.24, 1440–1443 (2005).
   PubMed Web of Science ®Google Scholar
• Verleden GM, Vanaudenaerde BM, Dupont LJ, Van Raemdonck DE. Azithromycin reduces airway neutrophilia and interleukin-8 in patients with bronchiolitis obliterans syndrome. Am. J. Respir. Crit. Care Med.174, 566–570 (2006).
   PubMed Web of Science ®Google Scholar
• Gottlieb J, Szangolies J, Koehnlein T, Golpon H, Simon A, Welte T. Long-term azithromycin for bronchiolitis obliterans syndrome after lung transplantation. Transplantation85, 36–41 (2008).
   PubMed Web of Science ®Google Scholar
• Fisher AJ, Rutherford RM, Bozzino J, Parry G, Dark JH, Corris PA. The safety and efficacy of total lymphoid irradiation in progressive bronchiolitis obliterans syndrome after lung transplantation. Am. J. Transplant.5, 537–543 (2005).
   PubMed Web of Science ®Google Scholar
• Benden C, Speich R, Hofbauer GF et al. Extracorporeal photopheresis after lung transplantation: a 10-year single-center experience. Transplantation86, 1625–1627 (2008).
   PubMed Web of Science ®Google Scholar
• Takemoto SK, Zeevi A, Feng S et al. National conference to assess antibody-mediated rejection in solid organ transplantation. Am. J. Transplant.4, 1033–1041 (2004).
   PubMed Web of Science ®Google Scholar
• Astor TL, Weill D, Cool C, Teitelbaum I, Schwarz MI, Zamora MR. Pulmonary capillaritis in lung transplant recipients: treatment and effect on allograft function. J. Heart Lung Transplant.24, 2091–2097 (2005).
   PubMed Web of Science ®Google Scholar
• Magro CM, Deng A, Pope-Harman A et al. Humorally mediated posttransplantation septal capillary injury syndrome as a common form of pulmonary allograft rejection: a hypothesis. Transplantation74, 1273–1280 (2002).
   PubMed Web of Science ®Google Scholar
• Ionescu DN, Girnita AL, Zeevi A et al. C4d deposition in lung allografts is associated with circulating anti-HLA alloantibody. Transpl. Immunol.15, 63–68 (2005).
   PubMed Web of Science ®Google Scholar
• Magro CM, Klinger DM, Adams PW et al. Evidence that humoral allograft rejection in lung transplant patients is not histocompatibility antigen-related. Am. J. Transplant.3, 1264–1272 (2003).
   PubMedGoogle Scholar
• Goers TA, Ramachandran S, Aloush A, Trulock E, Patterson GA, Mohanakumar T. De novo production of K-α1 tubulin-specific antibodies: role in chronic lung allograft rejection. J. Immunol.180, 4487–4494 (2008).
   PubMed Web of Science ®Google Scholar
• Girnita AL, McCurry KR, Iacono AT et al. HLA-specific antibodies are associated with high-grade and persistent-recurrent lung allograft acute rejection. J. Heart Lung Transplant.23, 1135–1141 (2004).
   PubMed Web of Science ®Google Scholar
• Palmer SM, Davis RD, Hadjiliadis D et al. Development of an antibody specific to major histocompatibility antigens detectable by flow cytometry after lung transplant is associated with bronchiolitis obliterans syndrome. Transplantation74, 799–804 (2002).
   PubMed Web of Science ®Google Scholar
• Hadjiliadis D, Chaparro C, Reinsmoen NL et al. Pre-transplant panel reactive antibody in lung transplant recipients is associated with significantly worse post-transplant survival in a multicenter study. J. Heart Lung Transplant.24, S249–S254 (2005).
   Google Scholar
• Appel JZ 3rd, Hartwig MG, Davis RD, Reinsmoen NL. Utility of peritransplant and rescue intravenous immunoglobulin and extracorporeal immunoadsorption in lung transplant recipients sensitized to hla antigens. Hum. Immunol.66, 378–386 (2005).
   PubMedGoogle Scholar
• Jordan SC, Vo A, Tyan D, Toyota M. Desensitization therapy with intravenous gammaglobulin (IVIG): applications in solid organ transplantation. Trans. Am. Clin. Climatol. Assoc.117, 199–211 (2006).
   PubMedGoogle Scholar
• Stegall MD, Gloor J, Winters JL, Moore SB, Degoey S. A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. Am. J. Transplant.6, 346–351 (2006).
   PubMed Web of Science ®Google Scholar
• Glotz D, Antoine C, Julia P et al. Intravenous immunoglobulins and transplantation for patients with anti-HLA antibodies. Transpl. Int.17, 1–8 (2005).
   Google Scholar
• Vo AA, Lukovsky M, Toyoda M et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N. Engl. J. Med.359, 242–251 (2008).
   PubMed Web of Science ®Google Scholar
• Mulley W, Hudson F, Tait B et al. A single low-fixed dose of rituximab to salvage renal transplants from refractory antibody-mediated rejection. Transplantation87, 286–289 (2009).
   PubMed Web of Science ®Google Scholar
• Perry DK, Burns JM, Pollinger HS et al. Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production. Am. J. Transplant.9, 201–209 (2009).
   PubMed Web of Science ®Google Scholar
• Vincenti F, Kirk AD. What’s next in the pipeline. Am. J. Transplant.8, 1972–1981 (2008).
   PubMed Web of Science ®Google Scholar
• Kotloff RM, Ahya VN, Crawford SW. Pulmonary complications of solid organ and hematopoietic stem cell transplantation. Am. J. Respir. Crit. Care Med.170, 22–48 (2004).
   PubMed Web of Science ®Google Scholar
• Mattner F, Fischer S, Weissbrodt H et al. Post-operative nosocomial infections after lung and heart transplantation. J. Heart Lung Transplant.26, 241–249 (2007).
   PubMedGoogle Scholar
• Aguilar-Guisado M, Givaldá J, Ussetti P et al.; RESITRA cohort. Pneumonia after lung transplantation in the RESITRA cohort: a multicenter prospective study. Am. J. Transplant.7, 1989–1996 (2007).
   PubMed Web of Science ®Google Scholar
• Valentine VG, Gupta MR, Walker JE Jr et al. Effect of etiology and timing of respiratory tract infections on development of bronchiolitis obliterans syndrome. J. Heart Lung Transplant.28, 163–169 (2009).
   PubMed Web of Science ®Google Scholar
• Botha P, Archer L, Anderson RL et al.Pseudomonas aeruginosa colonization of the allograft after lung transplantation and the risk of bronchiolitis obliterans syndrome. Transplantation85, 771–774 (2008).
   PubMed Web of Science ®Google Scholar
• Flume PA, Egan TM, Paradowski LJ, Detterbeck FC, Thompson JT, Yankaskas Jr. Infectious complications of lung transplantation: impact of cystic fibrosis. Am. J. Respir. Crit. Care Med.149, 1601–1607 (1994).
   PubMed Web of Science ®Google Scholar
• Bonnvillain RW, Valentine VG, Lombard GA, La Place SG, Dhillon G, Wang G. Post-operative infections in cystic fibrosis and non cystic fibrosis patients after lung transplantation. J. Heart Lung Transplant.26, 890–897 (2007).
   PubMedGoogle Scholar
• Aris RM, Routh JC, LiPuma JJ, Heath DG, Gilligan PH. Lung transplantation for cystic fibrosis patients with Burkholderia cepacia complex: survival linked to genomovar type. Am. J. Respir. Crit. Care Med.164, 2102–2106 (2001).
   PubMed Web of Science ®Google Scholar
• Boussaud V, Guillemain R, Grenet D et al. Clinical outcome following lung transplantation in patients with cystic fibrosis colonised with Burkholderia cepacia complex: results from two French centres. Thorax63, 732–737 (2008).
   PubMed Web of Science ®Google Scholar
• Alexander BD, Petzold EW, Reller LB et al. Survival after lung transplantation of cystic fibrosis patients infected with Burkholderia cepacia complex. Am. J. Transplant.8, 1025–1030 (2008).
   PubMed Web of Science ®Google Scholar
• Glanville AR, Gencay M, Tamm M et al.Chlamydia pneumoniae infection after lung transplantation. J. Heart Lung Transplant.24, 131–136 (2005).
   PubMed Web of Science ®Google Scholar
• Kotsimbos TC, Snell GI, Levvey B et al.Chlamydia pneumoniae serology in donors and recipients and the risk of bronchiolitis obliterans syndrome after lung transplantation. Transplantation79, 269–275 (2005).
   PubMed Web of Science ®Google Scholar
• Duncan SR, Paradis IL, Yousem SA et al. Sequelae of cytomegalovirus pulmonary infections in lung allograft recipients. Am. Rev. Respir. Dis.146, 1419–1425 (1992).
   PubMedGoogle Scholar
• Ettinger NA, Bailey TC, Trulock EP et al. Cytomegalovirus infection and pneumonitis. Impact after isolated lung transplantation. Washington University Lung Transplant Group. Am. Rev. Respir. Dis.147, 1017–1023 (1993).
   PubMed Web of Science ®Google Scholar
• Fishman JA, Rubin RH. Infection in organ-transplant recipients. N. Engl. J. Med.338, 1741–1751 (1998).
   PubMed Web of Science ®Google Scholar
• Beck S, Barrell BG. Human cytomegalovirus encodes a glycoprotein homologous to MHC class-I antigens. Nature331, 269–272 (1988).
   PubMedGoogle Scholar
• Burns LJ, Pooley JC, Walsh DJ, Vercellotti GM, Weber ML, Kovacs A. Intercellular adhesion molecule-1 expression in endothelial cells is activated by cytomegalovirus immediate early proteins. Transplantation67, 137–144 (1999).
   PubMedGoogle Scholar
• Craigen JL, Grundy JE. Cytomegalovirus induced up-regulation of LFA-3 (CD58) and ICAM-1 (CD54) is a direct viral effect that is not prevented by ganciclovir or foscarnet treatment. Transplantation62, 1102–1111 (1996).
   PubMed Web of Science ®Google Scholar
• Westall G, Kotsimbos T, Brooks A. CMV-specific CD8+ T-cell dynamics in the blood and the lung allograft reflect viral reactivation following lung transplantation Am. J. Transplant.6, 577–584 (2006).
   PubMedGoogle Scholar
• Shlobin O, West E, Lechtzin N et al. Persistent cytomegalovirus-specific memory responses in the lung allograft and blood following primary infection in lung transplant recipients. J. Immunol.176, 2625–2634 (2006).
   PubMedGoogle Scholar
• Weinberg A, Hodges TN, Li S, Cai G, Zamora MR. Comparison of PCR, antigenemia assay and rapid blood culture for detection and prevention of cytomegalovirus disease after lung transplantation. J. Clin. Microbiol.38, 768–772 (2000).
   PubMed Web of Science ®Google Scholar
• Pang XL, Fox JD, Fenton JM, Miller GG, Caliendo AM, Preiksaitis JK; American Society of Transplantation Infectious Diseases Community of Practice; Canadian Society of Transplantation. Interlaboratory comparison of cytomegalovirus viral load assays. Am. J. Transplant.9, 258–268 (2009).
   PubMed Web of Science ®Google Scholar
• Duncan SR, Grgurich WF, Iacono AT et al. A comparison of ganciclovir and acyclovir to prevent cytomegalovirus after lung transplantation. Am. Rev. Respir. Dis.150, 146–152 (1994).
   PubMed Web of Science ®Google Scholar
• Kelly JL, Albert RK, Wood DE, Raghu G. Efficacy of a 6-week prophylactic ganciclovir regimen and the role of serial cytomegalovirus antibody testing in lung transplant recipients. Transplantation59, 1144–1147 (1995).
   PubMed Web of Science ®Google Scholar
• Hertz MI, Jordan C, Savik SK et al. Randomized trial of daily versus three-times-weekly prophylactic ganciclovir after lung and heart-lung transplantation. J. Heart Lung Transplant.17, 913–920 (1998).
   PubMedGoogle Scholar
• Zamora MR. Cytomegalovirus and lung transplantation. Am. J. Transplant.4, 1219–1226 (2004).
   PubMed Web of Science ®Google Scholar
• Humar A, Kumar D, Preiksaitis J et al. A trial of valganciclovir prophylaxis for cytomegalovirus prevention in lung transplant recipients. Am. J. Transplant.5, 1462–1468 (2005).
   PubMed Web of Science ®Google Scholar
• Sun HY, Wagener MM, Singh N. Prevention of posttransplant cytomegalovirus disease and related outcomes with valganciclovir: a systematic review. Am. J. Transplant.8, 2111–2118 (2008).
   PubMed Web of Science ®Google Scholar
• Chmiel C, Speich R, Hofer M et al. Ganciclovir/valgnaciclovir prophylaxis decreases cytomegalovirus-related events and bronchiolitis obliterans syndrome after lung transplantation. Clin. Infect. Dis.46, 831–8390 (2008).
   PubMed Web of Science ®Google Scholar
• Valantine HA, Luikart H, Doyle R et al. Impact of cytomegalovirus hyoerimmune globulin on outcome after cardiothoracic transplantation: a comparative study of combined prophylaxis with CMV hyperimmune globulin plus ganciclovir versus ganciclovir alone. Transplantation72, 1647–1652 (2001).
   PubMed Web of Science ®Google Scholar
• Zamora MR, Davis D, Leonard C; CMV Advisory Board Expert Committee. Management of cytomegalovirus infection in lung transplant recipients: evidence-based recommendations. Transplantation80, 157–163 (2005).
   PubMed Web of Science ®Google Scholar
• Avery RK. Management of late, recurrent, and resistant cytomegalovirus in transplant recipients. Transplant Rev.21, 65–76 (2007).
   Google Scholar
• Lehto JT, Halme M, Tukiainen P, Harjula A, Sipponen J, Lautenschlager I. Human herpesvirus-6 and -7 after lung and heart-lung transplantation. J. Heart Lung Transplant.26, 41–47 (2007).
   PubMedGoogle Scholar
• Neurohr C, Huppmann P, Leuchte P et al. Human herpesvirus 6 in bronchalveolar lavage fluid after lung transplantation: a risk factor for bronchiolitis obliterans syndrome? Am. J. Transplant.5, 2982–2991 (2005).
   PubMed Web of Science ®Google Scholar
• Kumar D, Erdman D, Keshavjee S et al. Clinical impact of community-acquired respiratory viruses on bronchiolitis obliterans after lung transplant. Am. J. Transplant.5, 2031–2036 (2005).
   PubMed Web of Science ®Google Scholar
• Milstone AP, Brumble LM, Barnes J et al. A single-season prospective study of respiratory viral infections in lung transplant recipients. Eur. Respir. J.28, 131–137 (2006).
   PubMed Web of Science ®Google Scholar
• Hopkins P, McNeil K, Kermeen F et al. Human metapneumovirus in lung transplant recipients and comparison to respiratory syncytial virus. Am. J. Respir. Crit. Care Med.178, 876–881 (2008).
   PubMed Web of Science ®Google Scholar
• Shekar K, Hopkins PM, Kermeen FD, Dunning JJ, McNeil KD. Unexplained chronic anemia and leukopenia in lung transplant recipients secondary to parvovirus B19 infection. J. Heart Lung Transplant.27, 808–811 (2008).
   PubMedGoogle Scholar
• Gabardi S, Kubiak DW, Chandraker AK, Tullius SG. Invasive fungal infections and antifungal therapies in solid organ transplant recipients. Transplant Int.20, 993–1015 (2007).
   PubMed Web of Science ®Google Scholar
• Iversen M, Burton CM, Vand S et al.Aspergillus infection in lung transplant patients: incidence and prognosis. Eur J. Clin. Microbiol. Infect. Dis.26, 879–886 (2007).
   PubMed Web of Science ®Google Scholar
• Singh N, Husain S. Aspergillus infections after lung transplantation: clinical differences in type of transplant and implications for management. J. Heart Lung Transplant.22, 258–266 (2003).
   PubMed Web of Science ®Google Scholar
• Segal BH, Walsh TJ. Current approaches to diagnosis and treatment of invasive aspergillosis. Am. J. Respir. Crit. Care Med.173, 707–717 (2006).
   PubMed Web of Science ®Google Scholar
• Husain S, Paterson DL, Studer SM et al.Aspergillus galactomannan antigen in the bronchoalveolar lavage fluid for the diagnosis of invasive aspergillosis in lung transplant recipients. Transplantation83, 1330–1336 (2007).
   PubMed Web of Science ®Google Scholar
• Clancy CJ, Jaber RA, Leather HL et al. Bronchoalveolar lavage galactomannan in diagnosis of invasive pulmonary aspergillosis among solid-organ transplant recipients. J. Clin. Microbiol.45, 1759–1765 (2007).
   PubMed Web of Science ®Google Scholar
• Husain S, Zaldonis D, Kusne S, Kwak EJ, Paterson DL, McCurry KR. Variation in antifungal prophylaxis strategies in lung transplantation. Transpl. Infect. Dis.8, 213–218 (2006).
   PubMedGoogle Scholar
• Husain S, Paterson DL, Studer S et al. Voriconazole prophylaxis in lung transplant recipients. Am. J. Transplant.6, 3008–3016 (2006).
   PubMed Web of Science ®Google Scholar
• Maertens J, Raad I, Petrikkos G et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin. Infect. Dis.39, 1563–1571 (2004).
   PubMed Web of Science ®Google Scholar
• Denning DW, Marr KA, Lau WM et al. Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J. Infect.53, 337–349 (2006).
   PubMed Web of Science ®Google Scholar
• Herbrecht R, Denning DW, Patterson TF et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N. Engl. J. Med.347, 408–415 (2002).
   PubMed Web of Science ®Google Scholar
• Silveira FP, Kwak EJ, Paterson DL, Pilewski JM, McCurry KR, Husain S. Post-transplant colonization with non-aspergillus molds and risk of development of invasive fungal disease in lung transplant recipients. J. Heart Lung Transplant.27, 850–855 (2008).
   PubMedGoogle Scholar
• Chalermskulrat W, Sood N, Neuringer IP et al. Non-tuberculous mycobacteria in end stage cystic fibrosis: implications for lung transplantation. Thorax61, 507–513 (2006).
   PubMed Web of Science ®Google Scholar
• Malouf MA, Glanville AR. The spectrum of mycobacterial infection after lung transplantation. Am. J. Respir. Crit. Care Med.160, 1611–1616 (1999).
   PubMed Web of Science ®Google Scholar
• Chernenko SM, Humar A, Hutcheon M et al.Mycobacterium abscessus infections in lung transplant recipients: the international experience. J. Heart Lung Transplant.25(12), 1447–1455 (2006).
   PubMed Web of Science ®Google Scholar
• Olyaei AJ, de Mattos AM, Bennett WM. Nephrotoxicity of immunosuppressive drugs: new insight and preventive strategies. Curr. Opin. Crit. Care7, 384–389 (2001).
   PubMedGoogle Scholar
• Mason DP, Solovera-Rozas M, Feng J et al. Dialysis after lung transplantation: prevalence, risk factors and outcome. J. Heart Lung Transplant.26, 1155–1162 (2007).
   PubMedGoogle Scholar
• Canales M, Youssef P, Spong R et al. Predictors of chronic kidney disease in long-term survivors of lung and heart-lung transplantation. Am. J. Transplant.6, 2157–2163 (2006).
   PubMed Web of Science ®Google Scholar
• Ishani A, Erturk S, Hertz MI et al. Predictors of renal function following lung or heart–lung transplantation. Kidney Int.61, 2228–2234 (2002).
   PubMed Web of Science ®Google Scholar
• Esposito C, De Mauri A, Vitulo P et al. Risk factors for chronic renal dysfunction in lung transplant recipients. Transplantation84, 1701–1703 (2007).
   PubMedGoogle Scholar
• Stephany BR, Alao B, Budev M, Boumitri M, Poggio ED. Hyperlipidemia is associated with accelerated chronic kidney disease progression after lung transplantation. Am. J. Transplant.7, 2553–2560 (2007).
   PubMed Web of Science ®Google Scholar
• Flechner SM, Kobashigawa J, Klintmalm G. Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity. Clin. Transplant.22, 1–15 (2008).
   PubMed Web of Science ®Google Scholar
• Snell GI, Levvey BJ, Chin W et al. Sirolimus allows renal recovery in lung and heart transplant recipients with chronic renal impairment. J. Heart Lung Transplant.21, 540–546 (2002).
   PubMed Web of Science ®Google Scholar
• Demirjian S, Stephany B, Abu Romeh IS, Boumitri M, Yamani MH, Poggio ED. Conversion to sirolimus with calcineurin inhibitor elimination vs. dose minimization and renal outcome in heart and lung transplant recipients. Clin. Transplant.23(3), 351–360 (2009).
   PubMedGoogle Scholar
• Groetzner J, Wittwer T, Kaczmarek I et al. Conversion to sirolimus and mycophenolate can attenuate the progression of bronchiolitis obliterans syndrome and improves renal function after lung transplantation. Transplantation81, 355–360 (2006).
   PubMed Web of Science ®Google Scholar
• Formica RN Jr, Lorber KM, Friedman AL et al. The evolving experience using everolimus in clinical transplantation. Transplant. Proc.36, 495S–499S (2004).
   PubMedGoogle Scholar
• Letavernier E, Legendre C. mToR inhibitors-induced proteinuria: mechanisms, significance, and management. Transplant Rev. (Orlando)22, 125–130 (2008).
   PubMedGoogle Scholar
• Chhajed PN, Dickenmann M, Bubendorf L, Mayr M, Steiger J, Tamm M. Patterns of pulmonary complications associated with sirolimus. Respiration73, 367–374 (2006).
   PubMed Web of Science ®Google Scholar
• Groetzner J, Kur F, Spelsberg F et al.; Munich Lung Transplant Group. Airway anastomosis complications in de novo lung transplantation with sirolimus-based immunosuppression. J. Heart Lung Transplant.23, 632–638 (2004).
   PubMed Web of Science ®Google Scholar
• Valantine H. Is there a role for proliferation signal/mTOR inhibitors in the prevention and treatment of de novo malignancies after heart transplantation? Lessons learned from renal transplantation and oncology. J. Heart Lung Transplant.26, 557–564 (2007).
   PubMed Web of Science ®Google Scholar
• Tschopp O, Boehler A, Speich R et al. Osteoporosis before lung transplantation: association with low body mass index, but not with underlying disease. Am. J. Transplant.2, 167–172 (2002).
   PubMed Web of Science ®Google Scholar
• Stephenson A, Jamal S, Dowdell T et al. Prevalence of vertebral fractures in adults with cystic fibrosis and their relationship to bone mineral density. Chest130, 539–544 (2006).
   PubMedGoogle Scholar
• Grey AB, Ames RW, Matthews RD, Reid IR. Bone mineral density and body composition in adult patients with cystic fibrosis. Thorax48, 589–593 (1993).
   PubMedGoogle Scholar
• Aris RM, Neuringer IP, Weiner MA et al. Severe osteoporosis before and after lung transplantation. Chest109, 1176–1183 (1996).
   PubMed Web of Science ®Google Scholar
• Spira A, Gutierrez C, Chaparro C, Hutcheon MA, Chan CK. Osteoporosis and lung transplantation: a prospective study. Chest117, 476–481 (2000).
   PubMedGoogle Scholar
• Shane E, Papadopoulos A, Staron RB et al. Bone loss and fracture after lung transplantation. Transplantation68, 220–227 (1999).
   PubMed Web of Science ®Google Scholar
• Ferrari SL, Nicod LP, Hamacher J et al. Osteoporosis in patients undergoing lung transplantation. Eur. Respir. J.9, 2378–2382 (1996).
   PubMedGoogle Scholar
• Maalouf NM, Shane E. Osteoporosis after solid organ transplantation. J. Clin. Endocrinol. Metab.90, 2456–2465 (2005).
   PubMed Web of Science ®Google Scholar
• Henderson K, Eisman J, Keogh A et al. Protective effect of short-tem calcitriol or cyclical etidronate on bone loss after cardiac or lung transplantation. J. Bone Miner. Res.16, 565–571 (2001).
   PubMedGoogle Scholar
• Trombetti A, Gerbase MW, Spiliopoulos A, Slosman DO, Nicod LP, Rizzoli R. Bone mineral density in lung-transplant recipients before and after graft: prevention of lumbar spine post-transplantation-accelerated bone loss by pamidronate. J. Heart Lung Transplant.19, 736–743 (2000).
   PubMedGoogle Scholar
• Aris RM, Lester GE, Renner JB et al. Efficacy of pamidronate for osteoporosis in patients with cystic fibrosis following lung transplantation Am. J. Respir. Crit. Care Med.162, 941–946 (2000).
   PubMed Web of Science ®Google Scholar
• Cahill BC, O’Rourke MK, Parker S et al. Prevention of bone loss and fracture after lung transplantation: a pilot study. Transplantation72, 1251–1255 (2001).
   PubMedGoogle Scholar
• Braith RW, Conner JA, Fulton MN et al. Comparison of alendronate vs alendronate plus mechanical loading as prophylaxis for osteoporosis in lung transplant recipients: a pilot study. J. Heart Lung Transplant.26, 132–137 (2007).
   PubMedGoogle Scholar
• Legendre C, Marchetti P, Markell M et al. New-onset diabetes after transplantation: 2003 International consensus guidelines; proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003. Transplantation75, SS3–SS24 (2003).
   PubMedGoogle Scholar
• Ollech JE, Kramer MR, Peled N et al. Post-transplant diabetes mellitus in lung transplant recipients: incidence and risk factors. Eur. J. Cardiothorac. Surg.33, 844–848 (2008).
   PubMedGoogle Scholar
• Hadjiliadis D, Madill J, Chaparro C et al. Incidence and prevalence of diabetes mellitus in patients with cystic fibrosis undergoing lung transplantation before and after lung transplantation. Clin. Transplant.19, 773–778 (2005).
   PubMed Web of Science ®Google Scholar
• Pham PTT, Pham PCT, Lipshutz GS, Wilkinson AH. New onset diabetes mellitus after solid organ transplantation. Clin. Endocrinol. Metab.36, 873–890 (2007).
   Google Scholar
• Celik S, Doesch A, Erbel C et al. Beneficial effect of omega-3 fatty acids on sirolimus- or everolimus-induced hypertriglyceridemia in heart transplant recipients. Transplantation86, 245–250 (2008).
   PubMed Web of Science ®Google Scholar
• Mells G, Neuberger J. Reducing the risks of cardiovascular disease in liver allograft recipients. Transplantation83, 1141–1150 (2007).
   PubMed Web of Science ®Google Scholar
• Lipscombe J, Lewis GF, Cattran D, Bargman JM. Deterioration in renal function associated with fibrate therapy. Clin. Nephrol.55, 39–44 (2001).
   PubMed Web of Science ®Google Scholar
• Kariyawasam HH, Gyi KM, Hodson ME, Cohen BJ. Anaemia in lung transplant patient caused by parvovirus B19. Thorax55, 619–620 (2000).
   PubMedGoogle Scholar
• Hachem RR, Yusen RD, Chakinala MM, Aloush AA, Patterson GA, Trulock EP. Thrombotic microangiopathy after lung transplantation. Transplantation81, 57–63 (2006).
   PubMedGoogle Scholar
• Mal H, Veyradier A, Brugière O et al. Thrombotic microangiopathy with acquired deficiency in ADAMTS 13 activity in lung transplant recipients. Transplantation81, 1628–1632 (2006).
   PubMedGoogle Scholar
• Singh N, Gayowski T, Marino IR. Hemolytic uremic syndrome in solid-organ transplant recipients. Transpl. Int.9, 68–75 (1996).
   PubMedGoogle Scholar
• Davis RD Jr, Lau CL, Eubanks S et al. Improved lung allograft function after fundoplication in patients with gastroesophageal reflux disease undergoing lung transplantation. J. Thorac. Cardiovasc. Surg.125, 533–542 (2003).
   PubMed Web of Science ®Google Scholar
• Maurer JR. The spectrum of colonic complications in a lung transplant population. Ann. Transplant.5, 54–57 (2000).
   PubMedGoogle Scholar
• Reddy N, Wilcox CM. Diagnosis & management of cytomegalovirus infections in the GI tract. Expert Rev. Gastroenterol. Hepatol.1(2), 287–294 (2007).
   PubMedGoogle Scholar
• Gilljam M, Chaparro C, Tullis E et al. GI complications after lung transplantation in patients with cystic fibrosis. Chest123, 37–41 (2003).
   PubMed Web of Science ®Google Scholar
• Dellon ES, Morgan DR, Mohanty SP, Davis K, Aris RM. High incidence of gastric bezoars in cystic fibrosis patients after lung transplantation. Transplantation81, 1141–1146 (2006).
   PubMedGoogle Scholar
• Folch E, Shakoor H, Gomez J et al. Gastric bezoar after lung transplantation in non-cystic fibrosis patients and review of the literature. J. Heart Lung Transplant.26, 739–741 (2007).
   PubMedGoogle Scholar
• Young LR, Hadjiliadis D, Davis RD et al. Lung transplantation exacerbates gastroesophageal reflux disease. Chest124, 1689–1693 (2003).
   PubMed Web of Science ®Google Scholar
• Hadjiliadis D, Davis RD, Steele MP et al. Gastroesophageal reflux disease in lung transplant recipients. Clin. Transplant.17, 363–368 (2003).
   PubMed Web of Science ®Google Scholar
• D’Ovidio F, Mura M, Tsang M et al. Bile acid aspiration and the development of bronchiolitis obliterans after lung transplantation. J. Thorac. Cardiovasc. Surg.129, 1144–1152 (2005).
   PubMed Web of Science ®Google Scholar
• Ward C, Forrest IA, Brownlee IA et al. Pepsin like activity in bronchoalveolar lavage fluid is suggestive of gastric aspiration in lung allografts. Thorax60, 872–874 (2005).
   PubMed Web of Science ®Google Scholar
• D’Ovidio F, Mura M, Ridsdale R et al. The effect of reflux and bile acid aspiration on the lung allograft and its surfactant and innate immunity molecules SP-A and SP-D. Am. J. Transplant.6, 1930–1938 (2006).
   PubMed Web of Science ®Google Scholar
• Stovold R, Forrest IA, Corris PA et al. Pepsin, a biomarker of aspiration in lung allografts: a putative association with rejection. Am. J. Respir. Crit. Care Med.175, 1298–1303 (2007).
   PubMed Web of Science ®Google Scholar
• Blondeau K, Mertens V, Vanaudenaerde BA et al. Gastro–oesophageal reflux and gastric aspiration in lung transplant patients with or without chronic rejection. Eur. Respir. J.31, 707–713 (2008).
   PubMed Web of Science ®Google Scholar
• Lord RV, Ho S, Coleman MJ et al. Cholecystectomy in cardiothoracic organ transplant recipients. Arch. Surg.133, 73–79 (1998).
   PubMedGoogle Scholar
• Klima LD, Kowdley KV, Lewis SL et al. Successful lung transplantation in spite of cystic fibrosis-associated liver disease: a case series. J. Heart Lung Transplant.16, 934–938 (1997).
   PubMedGoogle Scholar
• Meachery G, DeSoyza A, Nichoson A et al. Outcomes of lung transplantation for cystic fibrosis in a large UK cohort. Thorax63, 725–731 (2008).
   PubMed Web of Science ®Google Scholar
• Barshes NR, DiBardino DJ, McKenzie ED et al. Combined lung and liver transplantation: the United States experience. Transplantation80, 1161–1167 (2005).
   PubMed Web of Science ®Google Scholar
• Shitrit AB, Kramer MR, Bakal I, Morali G, Ben Ari Z, Shitrit D. Lamivudine prophylaxis for hepatitis B virus infection after lung transplantation. Ann. Thorac. Surg.81, 1851–1852 (2006).
   PubMed Web of Science ®Google Scholar
• Sahi H, Zein NN, Mehta AC, Blazey HC, Meyer KH, Budev M. Outcomes after lung transplantation in patients with chronic hepatitis C virus infection. J. Heart Lung Transplant.26, 466–471 (2007).
   PubMedGoogle Scholar
• Todd JL, Lakey J, Howell D, Reidy M, Zaas D. Portal hypertension and granulomatous liver disease in a lung transplant recipient due to disseminated atypical mycobacterial infection. Am. J. Transplant.7, 1300–1303 (2007).
   PubMedGoogle Scholar
• Coley SC, Porter DA, Calamante F et al. Quantitative MR diffusion mapping and cyclosporine-induced neurotoxicity. Am. J. Neuroradiol.20, 1507–1510 (1999).
   PubMedGoogle Scholar
• Sklar EM. Post-transplant neurotoxicity: what role do calcineurin inhibitors actually play? Am. J. Neuroradiol.27, 1602–1603 (2006).
   PubMed Web of Science ®Google Scholar
• Goldstein LS, Haug MT 3rd, Perl J 2nd et al. Central nervous system complications after lung transplantation. J. Heart Lung Transplant.17, 185–191 (1998).
   PubMedGoogle Scholar
• Amital A, Shitrit D, Raviv Y et al. Development of malignancy following lung transplantation. Transplantation81, 547–551 (2006).
   PubMedGoogle Scholar
• Yousem SA, Randhawa P, Locker J et al. Posttransplant lymphoproliferative disorders in heart–lung transplant recipients: primary presentation in the allograft. Hum. Pathol.20, 361–369 (1989).
   PubMed Web of Science ®Google Scholar
• Paranjothi S, Yusen RD, Kraus MD, Lynch JP, Patterson GA, Trulock EP. Lymphoproliferative disease after lung transplantation: comparison of presentation and outcome of early and late cases. J. Heart Lung Transplant.20, 1054–1063 (2001).
   PubMed Web of Science ®Google Scholar
• Wigle DA, Chaparro C, Humar A, Hutcheon MA, Chan CK, Keshavjee S. Epstein–Barr virus serology and posttransplant lymphoproliferative disease in lung transplantation. Transplantation72, 1783–1786 (2001).
   PubMed Web of Science ®Google Scholar
• Ramalingam P, Rybicki L, Smith MD et al. Posttransplant lymphoproliferative disorders in lung transplant patients: the Cleveland Clinic experience. Mod. Pathol.15, 647–656 (2002).
   PubMed Web of Science ®Google Scholar
• Reams BD, McAdams HP, Howell DN, Steele MP, Davis RD, Palmer SM. Posttransplant lymphoproliferative disorder: incidence, presentation, and response to treatment in lung transplant recipients. Chest124, 1242–1249 (2003).
   PubMed Web of Science ®Google Scholar
• Gao SZ, Chaparro SV, Perlroth M et al. Post-transplantation lymphoproliferative disease in heart and heart-lung transplant recipients: 30-year experience at Stanford University. J. Heart Lung Transplant.22, 505–514 (2003).
   PubMed Web of Science ®Google Scholar
• Montone KT, Litzky LA, Wurster A et al. Analysis of Epstein–Barr virus-associated posttransplantation lymphoproliferative disorder after lung transplantation. Surgery119, 544–551 (1996).
   PubMed Web of Science ®Google Scholar
• Aris RM, Maia DM, Neuringer IP et al. Post-transplantation lymphoproliferative disorder in the Epstein–Barr virus-naive lung transplant recipient. Am. J. Respir. Crit. Care Med.154, 1712–1717 (1996).
   PubMed Web of Science ®Google Scholar
• Wheless SA, Gulley ML, Raab-Traub N et al. Post-transplantation lymphoproliferative disease: Epstein–Barr virus DNA levels, HLA-A3, and survival. Am. J. Respir. Crit. Care Med.178, 1060–1065 (2008).
   PubMed Web of Science ®Google Scholar
• Oertel SH, Verschuuren E, Reinke P et al. Effect of anti-CD 20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD). Am. J. Transplant.5, 2901–2906 (2005).
   PubMed Web of Science ®Google Scholar
• Knoop C, Kentos A, Remmelink M et al. Post-transplant lymphoproliferative disorders after lung transplantation: first-line treatment with rituximab may induce complete remission. Clin. Transplant.20, 179–187 (2006).
   PubMedGoogle Scholar
• Veness MJ, Quinn DI, Ong CS et al. Aggressive cutaneous malignancies following cardiothoracic transplantation: the Australian experience. Cancer85, 1758–1764 (1999).
   PubMed Web of Science ®Google Scholar
• Minai OA, Shah S, Mazzone P et al. Bronchogenic carcinoma after lung transplantation: characteristics and outcomes. J. Thorac. Oncol.12, 1404–1409 (2008).
   Google Scholar
• Sathy SJ, Martinu T, Youens K et al. Symptomatic pulmonary allograft Kaposi’s sarcoma in two lung transplant recipients. Am. J. Transplant.8, 1951–1956 (2008).
   PubMedGoogle Scholar
• Naderi AS, Farsian FN, Lee WM. Cholangiocarcinoma after lung transplantation in a patient with cystic fibrosis. Eur. J. Gastroenterol. Hepatol.20, 1115–1117 (2008).
   PubMedGoogle Scholar
• Kiberd BA, Keough-Ryan T, Clase CM. Screening for prostate, breast and colorectal cancer in renal transplant recipients. Am. J. Transplant.3, 619–625 (2003).
   PubMed Web of Science ®Google Scholar
• Monaco AP. The role of mTOR inhibitors in the management of posttransplant malignancy. Transplantation87, 157–163 (2009).
   PubMed Web of Science ®Google Scholar
• Gross CR, Savik K, Bolman RM 3rd et al. Long-term health status and quality of life outcomes of lung transplant recipients. Chest108, 1587–1159 (1995).
   PubMed Web of Science ®Google Scholar
• Vermeulen KM, van der Bij W, Erasmus ME, Duiverman EJ, Koëter GH, TenVergert EM. Improved quality of life after lung transplantation in individuals with cystic fibrosis. Ped. Pulm.37, 419– 426 (2004).
   PubMed Web of Science ®Google Scholar
• Ramsey SD, Patrick DL, Lewis S, Albert RK, Raghu G. Improvement in quality of life after lung transplantation: a preliminary study. Washington University Medical Center Lung Transplant Study Group. J. Heart Lung Transplant.14, 870–877 (1995).
   PubMed Web of Science ®Google Scholar
• Myaskovsky L, Dew MA, McNulty ML et al. Trajectories of change in quality of life in 12-month survivors of lung or heart transplant. Am. J. Transplant.6, 1939–1947 (2006).
   PubMedGoogle Scholar
• Sager JS, Kotloff RM, Ahya VN et al. Association of clinical risk factors with functional status following lung transplantation. Am. J. Transplant.6, 2191–2201 (2006).
   PubMedGoogle Scholar
• Munro PE, Holland AE, Bailey M, Button BM, Snell GI. Pulmonary rehabilitation following lung transplantation. Transplant. Proc.41, 292–295 (2009).
   PubMedGoogle Scholar
• Ericksson L. Heimburg, K, Mared L. Survival and functional status in patients 10 years after lung transplantation in Lund, Sweden. J. Heart Lung Transplant.26(Suppl. 1), S177 (2007).
   Google Scholar
• Rutherford RM, Fisher AJ, Hilton C et al. Functional status and quality of life in patients surviving 10 years after lung transplantation. Am. J. Transplant.5, 1099–1104 (2005).
   PubMed Web of Science ®Google Scholar
• Gerbase MW, Soccal PM, Spiliopoulos A, Nicod LP, Rochat T. Long-term health-related quality of life and walking capacity of lung recipients with and without bronchiolitis obliterans syndrome. J. Heart Lung Transplant.27, 898–904 (2008).
   PubMed Web of Science ®Google Scholar
• Petrucci L, Ricotti S, Michelini I et al. Return to work after thoracic organ transplantation in a clinically-stable population. Eur. J. Heart Failure9, 1112–1119 (2007).
   PubMedGoogle Scholar